GENSCRIPT BIO(HK:01548) Ge Long Hui·2025-08-23 11:13Core Insights - The company achieved a revenue of $519 million in H1 2025, representing an 81.9% increase, with a gross profit of approximately $320 million, up 140.1%, and an adjusted net profit of about $178 million, a significant increase of 509.6% [1] - The core business segments are showing a rapid recovery, particularly in life sciences services and products, which generated approximately $248 million in revenue, a growth of 11.3% [1] - The biopharmaceutical development (CDMO) segment saw a remarkable revenue increase of approximately $247 million, up 511.1%, primarily due to a substantial rise in licensing revenue [1][2] Revenue and Profit Analysis - The adjusted operating profit for life sciences services and products was approximately $46.35 million, a slight decrease of 3.2%, attributed to increased marketing transformation and R&D investments [1] - The industrial synthetic biology products generated revenue of $2.83 million, an increase of 8.4%, with an adjusted gross profit of about $11.4 million, up 3.6% [2] Project and Product Development - In H1 2025, the company secured 20 new CDMO projects for antibody protein drugs, with over 50% coming from global clients, and added 9 new IND approvals, totaling 56 [2] - The company continues to expand its NME portfolio, with over 30 antibody assets available for external licensing [2] Future Outlook - Revenue projections for 2025 to 2027 are estimated at $927 million, $803 million, and $905 million, reflecting year-on-year growth rates of 56.0%, -13.4%, and 12.6% respectively [2] - The biopharmaceutical CDMO segment is expected to return to an upward trajectory, with licensing revenue contributing positively to performance [2]